Samsung Biologics officials plan to have the company’s fifth bioproduction plant operational by April 2025, after having fully completed its latest biomanufacturing facility, Plant 4.
As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have the shortest construction timeline of 24 months, according to a company spokesperson. The new plant will add a capacity of 180,000 liters, and upon its completion, Samsung Biologics will maintain what it says is the world’s largest biomanufacturing capacity at 784,000 liters.
“Over a decade ago, we committed to bringing innovative solutions to our partners, and we’ve successfully delivered on that commitment with each new plant. Now building on this foundation, Plant 5 will leverage our unparalleled experience and expertise to deliver long-term success for our clients,” said John Rim, president and CEO of Samsung Biologics. “By expediting our capacity expansion and providing fully integrated services, we hope to close the gap between the demand and supply of life-saving biomedicines.”
Plant 5’s key features include seamless process integration and optimization as well as advanced automation, added Rim. The new plant reportedly will also incorporate sustainable systems to support the company’s commitment to achieving net zero greenhouse gas emissions by 2050 or earlier.
Plant 5 marks the first phase of Samsung Biologics’ second Bio Campus. In July 2022, the company purchased 357,360m2 of land for the expansion, which will feature an Open Innovation Center for biotech incubation and four plants for a total capacity of 720,000 liters.
All facilities will be connected to maximize output and efficiency with automated logistics and will incorporate next-generation technologies with fully digitalized systems, continued Rim. Upon the completion of Bio Campus II, Samsung Biologics will hold a total capacity of 1.324 million liters.